Disease Ibd Articles & Analysis: Older
21 news found
The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). Both One GI® and Iterative Scopes are fast-growing innovators in the gastroenterology space. ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...
This strategic partnership will lay the groundwork for future collaborations by using AIR to aid in the recruitment of patients for clinical trials in inflammatory bowel disease (IBD) and expanding Gastro Health’s clinical research capabilities. ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...
AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of clinical trials, but AI-R helps determine if patients are ...
About Iterative Scopes Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine for gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). The technology is also designed to potentially enhance colorectal cancer screenings. ...
About VE202 VE202 is a first-in-class defined bacterial consortium therapeutic candidate for the treatment of inflammatory bowel disease (IBD). It consists of 16 bacterial strains of the Clostridia class that were rationally selected. ...
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). ...
GI disorders include inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGID’s).1 GI dysfunctions are also prevalent during recovery from abdominal surgery which can lead to post-operative ileus (POI).2 Current motility technologies are typically limited in scope, invasive and only sample for a ...
About Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a debilitating, life-long condition that results from chronic inflammation of the intestinal tract. The most common forms of IBD are ulcerative colitis and Crohn's disease, which are both characterized by diarrhea, rectal bleeding, abdominal ...
Leveraging an extensive library of both public and proprietary molecular data, CytoReason's technology allows scientists to gain critical information on the body's functioning, and to address diseases such as IBD at the cellular level. IBD is a lifelong, chronic disease that affects the digestive system, and includes Crohn's ...
About SFA Therapeutics SFA Therapeutics, Inc., a spinout of Temple University, is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA is focused on proprietary drugs to treat chronic inflammation, which been implicated in a wide range of diseases, including ...
This workforce reduction will allow the company to focus its financial resources on its recurrent C. difficile infection (CDI) and autism spectrum disorder (ASD) development programs, two wholly-owned programs that Finch is prioritizing, along with its Takeda-partnered work in inflammatory bowel disease (IBD). Finch plans to provide guidance on the expected ...
This collaboration is a further validation of the Company’s technology following a major collaboration with Genentech/Roche in Inflammatory Bowel Disease (IBD), and one with University of Adelaide to develop novel bacterial therapy for Ulcerative Colitis (UC). ...
This collaboration is a further validation of the Company’s technology following a major collaboration with Genentech/Roche in Inflammatory Bowel Disease (IBD), and one with University of Adelaide to develop novel bacterial therapy for Ulcerative Colitis. ...
The Series C financing comes after four highly productive years in which Kallyope has built a portfolio of programs directed to novel targets in a wide array of diseases. In support of these programs, the company has established industry-leading capabilities in designing oral small-molecule drugs that selectively target the gut but not the rest of the body. ...
"These advantages undoubtedly will speed the drug's availability for a disease that kills hundreds of thousands of patients annually world-wide." While hepatocellular carcinoma afflicts 54,000 patients a year in the US (Cancer.net), the World Health Organization estimates the disease causes as many as 880,000 deaths per year globally–especially in China ...
” In recent decades, the United States and other developed countries have experienced an alarming rise in inflammation-linked conditions such as asthma, eczema, diabetes, allergies, inflammatory bowel diseases (IBD) and celiac disease. While some of these conditions primarily manifest during childhood or adulthood, the root of these ...
Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases, today announced that the Company has entered into an agreement to acquire the global rights to renzapride from EndoLogic LLC (“EndoLogic”). ...